AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sanofi completes acquisition of Vigil Neuroscience, expands neurology pipeline.
ByAinvest
Wednesday, Aug 6, 2025 1:11 am ET1min read
Sanofi has completed its acquisition of Vigil Neuroscience, expanding its neurology pipeline with VG-3927, a TREM2 agonist for Alzheimer's disease. The deal includes Vigil's preclinical pipeline for various neurodegenerative diseases. Sanofi previously invested $40 million in Vigil in June 2024 with the right of first negotiation for an exclusive license. The acquisition strengthens Sanofi's research in neurodegenerative diseases.
Sanofi has completed its acquisition of Vigil Neuroscience, Inc., bolstering its neurology pipeline with VG-3927, a novel oral TREM2 agonist for Alzheimer's disease. The acquisition, finalized on August 6, 2025, also includes Vigil's preclinical pipeline for various neurodegenerative diseases. The deal reinforces Sanofi's research efforts in these critical areas.In June 2024, Sanofi made a strategic investment of $40 million in Vigil, which included the exclusive right of first negotiation for an exclusive license to research, develop, manufacture, and commercialize VG-3927 [1]. Under the terms of the acquisition agreement, Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash, representing an equity value of approximately $470 million on a fully diluted basis [2].
Additionally, Vigil's shareholders received a non-transferable contingent value right (CVR) per Vigil share, entitling them to a deferred cash payment of $2 upon the first commercial sale of VG-3927. The second clinical program, VGL101, was not included in the acquisition.
Sanofi's acquisition of Vigil Neuroscience is expected to enhance its research capabilities in neurodegenerative diseases. The company aims to leverage Vigil's preclinical pipeline to strengthen its overall research portfolio and potentially bring innovative therapies to market.
The acquisition does not impact Sanofi's financial guidance for 2025, as previously communicated [1]. Sanofi continues to focus on its mission of improving people’s lives through innovative medicines and vaccines, guided by its deep understanding of the immune system.
References:
[1] https://www.globenewswire.com/news-release/2025/08/06/3128014/0/fr/Communiqu%C3%A9-de-presse-Sanofi-finalise-l-acquisition-de-Vigil-Neuroscience-Inc.html
[2] https://www.globenewswire.com/news-release/2025/08/06/3128014/0/en/Press-Release-Sanofi-completes-the-acquisition-of-Vigil-Neuroscience-Inc.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet